Salute e Benessere

90th CMEF in Shenzhen Showcases Global MedTech Innovations and Insights

A notable feature of this year's exhibition is a strategic agreement. In June 2025, RSE will host THE HEALTH INDUSTRY SERIES – ASEAN (tHIS ASEAN) co-located with APHM. The Southeast Asian healthcare market is set for rapid expansion, with an expected annual growth rate of 10-12%. This partnership seeks to unite healthcare professionals and industry leaders in Southeast Asia, encouraging cooperation and progress to improve global health standards. A notable feature of this year's exhibition is…

SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene…

The trial, conducted at nine academic sites in the United States has been successfully led by three principal investigators Dr. V. Sondak M.D., Chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, Dr. T. Hieken, M.D., Surgical Oncologist and Professor of Surgery, Mayo Clinic, and Dr. M. Egger M.D., M.P.H., Associate Professor, Surgical Oncologist UofL Health Brown Cancer Center Louisville. The trial validated the predictive power of the CP-GEP (Clinical-Pathologic and Gene…

World Thrombosis Day raises global awareness of blood clot dangers through…

The campaign has partnered with more than 6,000 organizations worldwide to implement impactful initiatives. This year, World Thrombosis Day emphasizes the impact on women's health with the launch of a new global survey aimed at understanding women's awareness of their health risks. The campaign has partnered with more than 6,000 organizations worldwide to implement impactful initiatives. This year, World Thrombosis Day emphasizes the impact on women's health with the launch of a new global...

BioVaxys Announces Marketing Program

As consideration for the Services, the Company will pay OTB a cash fee in advance in the amount of $130,000. The Company will not issue any securities to OTB as compensation for the Services. Pursuant to the terms of the Agreement, OTB will provide the Services in order to communicate information about the Company, including, but not limited to: As consideration for the Services, the Company will pay OTB a cash fee in advance in the amount of$130,000. The Company will not issue any...

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Oct.11, 2024(GLOBE NEWSWIRE) --Paris, France, October 11, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of...

Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis…

In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased, clearly noticeable well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years respectively after their owners reported significant improvement in quality of life when receiving the treatment in addition to conventional treatments…

Pharmaceutical Filtration Industry Forecasts $18.1 Billion Market Size by 2029

The global pharmaceutical filtration market is comprehensively analyzed based on various segments including type (sterile and non-sterile), product (filters, systems, others), mechanism (surface filtration, depth filtration, crossflow filtration), category (liquid and gas filtration, air filtration), and technology (ultrafiltration, microfiltration, nanofiltration, others). The market also considers application areas such as drug manufacturing, purification, and quality control. Regionally, the…

Cell Therapy 2.0: The Rise of Automation and Closed Systems

This report explores the automated and closed cell therapy market, highlighting its current and future potential. It analyzes the factors driving growth, challenges, and opportunities. The report also: This report explores the automated and closed cell therapy market, highlighting its current and future potential. It analyzes the factors driving growth, challenges, and opportunities. The report also: • Predicts market trends up to 2029 • Examines the competitive landscape • Analyzes...

PCR Technologies Market to Hit USD 21.89 Billion by 2030 with 7.7% CAGR |…

Browse in-depth TOC on "PCR Technologies Market" Browse in-depth TOC on "PCR Technologies Market" 237 - Tables 68 - Figures 304 - Pages Recent improvements in PCR technology are, therefore, increasingly changing the industry landscape through a combination of innovative developments and regulatory shifts. A great new trend in the industry involves an increasing use of digital PCR (dPCR), ideally used in high sensitivity and accuracy in the detection and quantification of…

ChemoMetec's potential acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 278 11 October 2024ChemoMetec's potential acquisition of Ovizio Imaging Systems SAAs mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company Ovizio Imaging Systems SA. As also stated in the announcement, ChemoMetec expected to complete the due diligence within three weeks and most likely to complete the acquisition, if the outcome was positive.The mentioned due diligence and negotiations on the final...

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the…

Halle (Saale) / Munich, Germany, October 11, 2024– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company's abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat...

EveryMatrix completes the recommended public cash offer to the shareholders of…

Shares tendered and acquired outside the Offer as well as sale commitments Shares tendered and acquired outside the Offer as well as sale commitments 3,046,040 shares, corresponding to 85.65 per cent of all shares and votes in Fantasma, were tendered in the Offer during the acceptance period that ended on10 October 2024. Following the announcement of the Offer, EveryMatrix has acquired 150,000 shares, corresponding to 4.22 per cent of all shares and votes in Fantasma, outside the Offer...

Hugues Péribère of Overseed Named in the 2024 Business Worldwide Magazine CEO…

Péribère's achievement highlights his exemplary work in leading Overseed, a pioneering force in France's biopharmaceutical landscape, particularly in medical cannabis production. Under his leadership, Overseed has emerged as a frontrunner in the development of pharmaceutical-grade medical cannabis in France. With expertise in genetics, agronomy, and pharmaceutical chemistry, Overseed is set to become the first French manufacturer of 100% cannabis-based medicines, helping to shape the future of…

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Sanofi in discussions to sell a controlling stake in OpellaParis, October 11, 2024 .Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.Should these discussions lead to a positive outcome, any agreement would be subject to the completion of the necessary social processes.Further updates on the potential separation of Opella will be provided in due course,...

FDA approves Roche's Itovebi, a targeted treatment for advanced hormone…

Approval is based on Phase III INAVO120 results, showing the Itovebi™(inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting 1 This approval helps address an urgent unmet need in breast cancer for people with aPIK3CAmutation, one of the most commonly mutated genes in HR-positive disease, associated with poor prognosis 2,3Itovebi is Roche's first targeted therapy approved for...

NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare…

NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that three abstracts have been accepted for oral presentation, and a fourth abstract selected for poster presentation, at the American Association of...

CLÉ DE PEAU BEAUTÉ ANNOUNCES SACHIKO NAKAJIMA AS RECIPIENT OF THE POWER OF…

The annual Power of Radiance Awards recognizes and celebrates women who are taking action by advocating for girls' education in their communities. The Awards were founded in 2019, and are based on Clé de Peau Beauté's belief that the key to a better world lies in unlocking the potential of girls especially through STEAM education. The annual Power of Radiance Awards recognizes and celebrates women who are taking action by advocating for girls' education in their communities. The Awards were...

Explore "Intensive Care Airway Clearance Technology" with BMC at ESICM 2024

Continuous exploration and exchange in clinical advancements with Leading Experts Continuous exploration and exchange in clinical advancements with Leading Experts For patients undergoing mechanical ventilation, the natural cough reflex is often suppressed due to reduced respiratory muscle function, leading to an increased risk of airway secretion accumulation. This can result in elevated respiratory resistance, inadequate ventilation, and potentially severe complications such as...

Immatics Announces Pricing of $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024– Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering...

Global Pediatric Drugs Market is Predicted to Resister Growth at a CAGR of ~5%…

Key Takeaways from the Pediatric Drugs Market Report Key Takeaways from the Pediatric Drugs Market Report To read more about the latest highlights related to the pediatric drugs market, get a snapshot of the key highlights entailed in the Global Pediatric Drugs Market Report Pediatric Drugs Overview Pediatric drugs are medications specifically formulated and dosed for use in children, addressing the unique physiological and developmental needs of this population. Unlike adults,...

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears…

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report Request a sample and discover the recent advances in mCRPC treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Report The mCRPC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mCRPC drugs, inactive and dormant assets,...

Procedure of the Annual General Meeting

ANNOUNCEMENT NO. 277 10 October 2024Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsjællands KonferenceCenter.At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2023/24 was approved, and the Board of Directors and the Executive Board were granted discharge.The Annual General Meeting approved the...

EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its…

Press Release €451M Revolving Credit Facility refinanced with a maturity extended to February 2029Issuance of a €200M Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi€54M product capacity reservation for five products and further amendments to the global Manufacturing and Supply Agreement (MSA) agreed with Sanofi “The completion of the financing is an instrumental step in the execution of EUROAPI's strategic roadmap”said Ludwig de Mot, Chief...

Monthly information related to total number of voting rights and shares…

Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 2024...

Altri Comunicati